

**For Immediate Release:**

January 28, 2009

**Contact:**

Mary Kuramoto

513-579-9911 X 2523

m.kuramoto@medpace.com

**Medpace, Inc. celebrates the first year success at the Medpace Clinical Pharmacology Unit (MCPU)**

CINCINNATI (January 28, 2009) — Medpace celebrated an important milestone in its continuing growth and success as a full-service global clinical development organization - the one-year anniversary of the Medpace Clinical Pharmacology Unit (MCPU) located in Cincinnati, OH. Within the first year of operation, the Medpace CPU has attracted top level scientific projects including Phase I endocrinology and cardiology projects from a variety of sponsors and positioned themselves as an emerging industry leader in early phase studies. Medpace CPU is a 63-bed, 30,000 square-foot facility. The CPU is equipped with a state-of-the-art Mortara 12-lead telemetry system as well as highly developed diagnostic and surveillance equipment. The Medpace CPU is located in close proximity to an onsite Medpace bioanalytical lab, central lab and ECG core lab.

Medpace Clinical Pharmacology continues to strengthen their therapeutic expertise by adding industry leaders to their team. In the past year Medpace added Dr. Bernard Ilson to the current team of experts, Dr. Jim Wei and Dr. Doug Logan, expanding their clinical pharmacology expertise in therapeutically focused areas of cardiology, endocrinology and nephrology. Dr. Ilson's experience includes 21 years of experience in the pharmaceutical industry, spanning early phase and later phase development of cardiovascular, metabolic and renal drugs. Dr. Jim Wei brings ten years of experience as a clinical pharmacologist in the Metabolic and Endocrine division of the FDA. Dr. Wei joined Medpace in 2007. Dr. Logan brings 27 years of clinical experience in internal medicine and joined Medpace in 2006. This combination of medical expertise along with the MCPU world-class facility, allows Medpace to continue expanding its existing Phase II-IV experience to include early phase development, providing full-service capabilities to the pharmaceutical and biotech industries.

"With the help of other Medpace groups, Medpace Bioanalytical Laboratories, Medpace Cardiovascular Core Laboratory, and Medpace Reference Laboratory, we will continue to expand our capacity to conduct first-in-human studies, and proof-of-concept (POC) studies in focused therapeutic areas such as diabetes and cardiovascular fields," said Dr. Jim Wei, Director Clinical Pharmacology. "In addition to these studies, we will launch a new capability to conduct glucose clamp studies in 2009."

Medpace CPU has also added to their broad database of volunteers over the past year including healthy elderly volunteers and patients with type 2 diabetes, hyperlipidemia, obesity, and hypertension and has conducted various early phase studies from bioequivalence and complex PK-PD studies to proof-of-concept studies.

"Our ability to provide top level clinical pharmacology services for our sponsors has been met with early success and will continue to be a focus of strategic growth for Medpace," said Dr. August Troendle, Medpace President and CEO. "Our ability to provide deep therapeutic expertise combined with broad trial experience for our sponsors ultimately makes us the provider of choice for Phase I and IIa projects in the drug development arena."

###

## **ABOUT MEDPACE**

Medpace is a leading global full-service clinical research organization led by top therapeutic and regulatory experts who are driven to further the advancement of pharmaceutical agents for use in cardiology, metabolism, oncology, and nephrology. Medpace has assembled the industry's most experienced and therapeutically focused team to execute at every level of the company's operations, providing complete and seamless drug development services.

Through specialized regulatory expertise and therapeutically focused clinical operations, Medpace creates strategic partnerships with pharmaceutical and biotechnology companies to provide the most efficient and cost-effective path to drug development – from program planning and execution to product approval.

With more than 700 employees and clinical trial experience in over 40 countries, Medpace has the global reach and capability to conduct studies and navigate regulatory requirements worldwide within the core therapeutic areas of cardiology, metabolism, oncology, and nephrology.

Medpace provides centralized image management and reading from Imagepace, central laboratory and therapeutically specialized testing from Medpace Reference Laboratories, complete bioanalytical services in all stages of drug development from Medpace Bioanalytical Laboratories, and Phase I / IIa research services from Medpace Clinical Pharmacology.

**Visit the Medpace website at [www.medpace.com](http://www.medpace.com)**